OTTAWA, May 4 /CNW/ - MDS Nordion, a leading global provider of medical
isotopes and radiopharmaceuticals used in molecular medicine, TRIUMF, Canada's
national laboratory for particle and nuclear physics, and the University of
British Columbia, today announced that they have entered into a three-year
research-and-development partnership to pursue the development of new
diagnostic imaging agents - medical isotope products using technology based on
radiometals and chelates.
Radiometals are a class of medical isotopes that has been the backbone of
nuclear medicine for decades, and are currently used in 80% of nuclear
medicine procedures. Scientists will combine select radiometals with newly
developed chelates - substances that bind to radiometals and protect them as
they are carried through the body - with the goal to provide new agents for
the diagnoses and treatment of cancer and heart disease.
"This strategic partnership with TRIUMF and UBC is expected to accelerate
innovation, which could provide the opportunity to commercialize new molecular
medicine products," said MDS Nordion President Steve West. "Our combined
capabilities and technical expertise will create a dynamic setting in which to
develop new tools for physicians to detect disease earlier and more precisely,
and to offer breakthrough treatments for patients."
Under the terms of the agreement, MDS Nordion, TRIUMF and UBC provide
complementary expertise in chelate design and synthesis, analytical chemistry
and radiochemistry. MDS Nordion will provide required medical isotopes
produced at its facility on the TRIUMF campus. Each partner will provide
funding and in-kind contributions for the project, and the Natural Sciences
and Engineering Research Council of Canada (NSERC) will provide a grant
through its co-operative research-and-development program.
"With a partnership that has spanned more than 30 years, TRIUMF and MDS
Nordion have been focused on medical isotopes as a raw material," said TRIUMF
Director Nigel Lockyer. "We are now expanding this relationship to
collaboratively develop value-added products - isotopes combined with specific
molecules - to drive new innovations in the field of molecular imaging
MDS Nordion, TRIUMF and UBC researchers will explore alternative
technologies, as well as experiment with new modalities for diagnostic imaging
"UBC is delighted to work with MDS Nordion and TRIUMF on this research
project," said Don Brooks, Associate Vice-President Research, at UBC "It is
partnerships like this one, enabled by NSERC, that help connect basic research
with real-world value. Each of these partners brings something unique and
important to this initiative."
About the University of British Columbia
The University of British Columbia is one of Canada's largest public
research and teaching institutions and ranks consistently among the top 35
universities in the world. It offers a range of innovative undergraduate,
graduate and professional programs in the arts, sciences, medicine, law,
commerce and other faculties. UBC ranks in the top 10 universities in North
America and number one in Canada for commercializing research, and for its
patent activity in the life sciences. For more information, visit: www.ubc.ca.
TRIUMF is Canada's national laboratory for particle and nuclear physics.
Located on the south campus of the University of British Columbia, TRIUMF is
owned and operated as a joint venture, via a contribution through National
Research Council Canada and supported by the Province of British Columbia, by
a consortium of the following Canadian universities: University of Alberta,
University of British Columbia, Carleton University, University of Manitoba,
l'Université de Montréal, Simon Fraser University, University of Toronto, and
University of Victoria. To learn more about TRIUMF, go to
About MDS Nordion
MDS Nordion, a business unit of MDS Inc., is a global leader in providing
medical isotopes for molecular and diagnostic imaging, radiotherapeutics and
sterilization technologies for medical products that benefit the lives of
millions of people in more than 50 countries around the world. MDS Nordion
products and services are used on a daily basis by pharmaceutical and
biotechnology companies, medical-device manufacturers, hospitals, clinics and
research laboratories. Find out more at www.mdsnordion.com
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that
provides market-leading products and services that our customers need for the
development of drugs, and the diagnosis and treatment of disease. We are a
leading global provider of pharmaceutical contract research, medical isotopes
for molecular imaging, radiotherapeutics, and analytical instruments. MDS has
more than 5,000 highly skilled people in 29 countries. Find out more at
www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.
For further information:
For further information: MEDIA: Shelley Maclean, (613) 592-3400, ext.
2414, email@example.com; INVESTORS: Kim Lee, (416) 213-4721,
firstname.lastname@example.org; CONTACT TRIUMF: Dr. Timothy I. Meyer, (604) 222-7674,
email@example.com; CONTACT UBC: Brian Lin, (604) 818-5685, firstname.lastname@example.org